Mandatory notification of trade

28. Oct 2025 | 1 min read

Moss, 28 October 2025

Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction has been completed by a primary insider in Gentian:

Matti Heinonen, Chief Executive Officer and primary insider in Gentian, has purchased 5,000 shares in Gentian at NOK 54.86 per share. Mr. Heinonen owns 5,000 shares and 100,000 options after this transaction.

PDMR notification pursuant to the EU Market Abuse Regulation Article 19 is attached.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article 19 and Euronext Oslo Rule Book II.

For further information, please contact: Njaal Kind, Group CFO, njaal.kind@gentian.no, +47 91 90 65 25

You may also read


May 06, 2026 - Ole Sørlie

Gentian Diagnostics: First quarter 2026 report

Moss, 6 May 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests,..

May 06, 2026 - Ole Sørlie

Gentian Diagnostics ASA terminates NT-proBNP assay development

Moss, 6 May 2026 Following a comprehensive review of performance data and market dynamics, Gentian..

May 06, 2026 - Ole Sørlie

Gentian Diagnostics: Ex dividend NOK 0.60 today

Moss, 6 May 2026 The shares in Gentian Diagnostics ASA will be traded ex dividend NOK 0.60 as of today. The..